Actions
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
1
Neutral
7
Bullish
6
Bearish
10
Neutral
7
Bullish
29
Bearish
9
Neutral
0
Bullish
23
Sun Pharmaceutical Industries Ltd (SUNPHARMA) is currently trading at 1,870.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sun Pharmaceutical Industries is a global pharmaceutical company producing generic, branded-generic, specialty, innovative, over-the-counter, API, and complex technology-intensive medicines across more than 2,000 molecules and multiple dosage forms. Its operations span India, the United States, emerging markets, and other international regions, supported by 40 manufacturing facilities worldwide. Q2 FY27 sales rose 11.8% to INR 161.0 billion, while adjusted net profit reached INR 31.6 billion. Growth was broad-based, led by India formulations, emerging markets, and the innovative-medicines portfolio, although reported profitability was affected by litigation provisions, Organon transaction costs, higher taxation, and the absence of prior-year lenalidomide benefits. India remains the strongest operating engine, with quarterly sales growth of 17.3%, volume growth materially ahead of the market, and market share increasing to 8.6%. Management attributed performance to prescription expansion, new products, scientific promotion, field-force expansion, and brand building rather than relying solely on price increases. The United States faced an 8.2% year-on-year decline because of lenalidomide erosion and slower Ilumya momentum, but five generic launches supported sequential growth. The new psoriatic-arthritis indication for Ilumya, improving Unloxcyt access, and growing Leqselvi adoption are intended to rebuild specialty growth over the next several quarters. Sun Pharma is balancing a transformational Organon acquisition with continued investment in proprietary medicines and international launches. Q2 R&D spending was INR 7.8 billion, or 4.8% of sales, below the intended pace, but management expects a significant second-half ramp-up while retaining the original FY27 growth guidance.
Over the past 52 weeks, Sun Pharmaceutical Industries Ltd has traded between a low of ₹1,583.60 and a high of ₹2,047.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sun Pharmaceutical Industries Ltd has a market capitalization of approximately 4,48,687.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sun Pharmaceutical Industries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 40.65 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4,48,687.64 Cr, Sun Pharmaceutical Industries Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sun Pharmaceutical Industries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sun Pharmaceutical Industries Ltd is 40.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Sun Pharma expects the Organon acquisition to close in Q4 FY27. On October 30, 2026, management also described the timetable as an early-2027 close, subject to remaining customary closing conditions.
Sun Pharma said sales can begin after each European country completes its pricing and reimbursement process. Management said that process usually takes 6 to 12 months, depending on the market and queries on the submitted dossier.
Sun Pharma reported India formulations sales of Rs 5,552.3 crore in Q2 FY27, up 17.3% year on year. The India business accounted for 34.5% of Sun Pharma’s consolidated sales in the quarter.
Sun Pharma said the Q2 FY27 slowdown came from a combination of market factors and execution issues. Management did not identify the individual execution problems or disclose Ilumya's US revenue. It said interventions have already been put in place.

View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Pharmaceuticals & Biotechnology
Pharmaceuticals
4,48,688 Cr
Low Risk
40.7
39.0
2.2
5.0
2,047.55
1,583.60
Sales CAGR
Profit CAGR
ROE
ROCE
